MetaCap

Aardvark Therapeutics (AARD) vs Incannex Healthcare (IXHL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Incannex Healthcare (IXHL) has outperformed Aardvark Therapeutics (AARD) over the past year, losing 80.3% versus a loss of 90.2%. Incannex Healthcare is the larger company by market cap ($23.3 million vs $20.2 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AARD-90.15%IXHL-80.32%
+77%-11%-98%
Nov 21, 20251 yearNov 20, 2026
AARD-93.06%IXHL-96.52%
+28%-37%-102%
Feb 10, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AARD versus IXHL key metrics
MetricAARDIXHL
Share price$0.9226$1.86
Market cap$20.20M$23.34M
1-day change-7.74%+6.90%
YTD return-92.97%-82.68%
1-year return-90.15%-80.32%
EPS (TTM)$-3.33$-1.25
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$0
Revenue growth (YoY)—-100.00%
Net income (latest FY)$-57.59M$-19.30M
52-week high$16.60$14.91
52-week low$0.90$1.61
Distance from 52-week high-94.44%-87.53%
Analyst consensusbuystrong_buy
Avg. price target upside+1104.21%+904.30%
Average volume643.53K91.61K
Shares outstanding21.89M12.55M
Employees2812
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Aardvark Therapeutics

AARD stock →

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc.

Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees

About Incannex Healthcare

IXHL stock →

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

AARD vs IXHL FAQ

Which is bigger, Aardvark Therapeutics or Incannex Healthcare?

Incannex Healthcare (IXHL) is larger, with a market capitalization of $23.34M compared with $20.20M for Aardvark Therapeutics (AARD).

Which stock has performed better over the past year, AARD or IXHL?

IXHL returned -80.32% over the past 12 months, compared with -90.15% for AARD (price return, excluding dividends). Past performance does not predict future results.

Are Aardvark Therapeutics and Incannex Healthcare in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons